GlassScriptPhysician profile
May Catherine Rodriguez
NPI 1902569338
$1,937.55
in general payments reported to CMS, 2019-2025
15 companies · $461 in 2025
The $461 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $510 · 2023: $358 · 2024: $609 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,427.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $629.46 | 2022-2025 | Farxiga |
| Calliditas Therapeutics US INC. | $293.79 | 2022-2025 | Tarpeyo |
| Vifor Pharma, INC. | $274.69 | 2022-2023 | Veltassa |
| Mallinckrodt Hospital Products INC. | $146.44 | 2023-2025 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $115.03 | 2022-2025 | |
| Ardelyx, INC. | $113.61 | 2023-2025 | Ibsrela |
| Opko Pharmaceuticals, LLC | $101.64 | 2023-2024 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $63.87 | 2023-2024 | Jynarque |
| Aurinia Pharma U.S., INC. | $49.26 | 2023-2024 | Lupkynis |
| Lilly USA, LLC | $41.53 | 2024-2025 | Jardiance |
| Amgen INC. | $25.22 | 2023 | Parsabiv, Tavneos |
| Takeda Pharmaceuticals U.S.A., INC. | $24.90 | 2025 | Gattex |
| Alexion Pharmaceuticals, INC. | $23.63 | 2022 | |
| Glaxosmithkline, LLC. | $19.83 | 2023 | Benlysta |
| Ani Pharmaceuticals, INC. | $14.65 | 2025 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw May Catherine Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.